Watch this webinar with Nikunjkumar Patel, Oliver Hatley, and Matthew Harwood to learn how the latest updates in the Simcyp Simulator v17 will help provide insights that support developing safer, more effective medications.
Scientists at the Aarhus University in Denmark used the Simcyp Simulator to support a forensic toxicological assessment of a fatal drug poisoning case.
Analysis of in vitro data from whole cell systems and dissolution studies is complex, challenging and time consuming. Yet accurate data analysis and informed data interpretation early in drug development is crucial. Existing tools have mainly been developed for broader data analysis and are not specifically designed for in vitro systems. These software tools do not readily support analysis […]
It may be 2016, but we just held the 17th annual Simcyp Consortium meeting in Sheffield, UK. This year’s gathering had >120 attendees with representatives from all but one of the 34 consortium member companies joining. The opening session reviewed the progress made by the Simcyp staff toward the field of regulatory science, physiologically-based pharmacokinetic […]
The Simcyp™ Population-based Simulator streamlines drug development through the modelling and simulation of physiologically-based pharmacokinetics (PK) and pharmacodynamics (PD) in virtual patient populations. It incorporates numerous databases containing human physiological, genetic and epidemiological information. By integrating this information with in vitro or clinical data, the Simulator can predict PK/PD behavior in ‘real-world’ populations. It can be used to select […]
Acquisition of Simcyp adds important predictive science methodologies to Certara’s translational science approach to drug development. ST. LOUIS, MO –March 13, 2012 – Certara™, a Vector Capital portfolio company and a leading provider of drug discovery and development software and scientific consulting services, today announced the completion of its acquisition of UK-based Simcyp Limited. Simcyp […]
PRINCETON, NJ – Dec. 6, 2016 – Certara today announced that it is establishing a new Quantitative Systems Toxicology (QST) Initiative. That initiative, which will be managed by the company’s Simcyp division, leverages its Quantitative Systems Pharmacology (QSP) expertise.
The Effects of CYP3A4 Inhibition on Erlotinib Pharmacokinetics: Computer-based Simulation (Simcyp) Predicts In Vivo Metabolic Inhibition
Acquisition will add powerful preclinical research capability to Certara’s translational science approach to drug development. ST. LOUIS, MO – February 24, 2012 – Certara™, a leading provider of drug discovery and development software and scientific consulting services and a Vector portfolio company, today announced agreement to acquire Simcyp Limited. Simcyp is a UK-based, leading research company […]
Will the 21st century go down in history as the “Chinese Century”? If the status of its pharmaceutical industry is a barometer for China’s global position, then the answer may be “yes.” The size of the Chinese pharmaceutical market is second only to the US. In 2014, it was worth $105 billion. By 2020, the […]